A noteworthy prognostic marker in extensive small cell lung cancer: lymphocyte/C-reactive protein ratio

Authors : Figen ÖZTÜRK ERGÜR, Ayperi ÖZTÜRK, Melahat UZEL ŞENER, Zeynep Tilbe SAYMAZ, Nihal MUTLU

Pages : 341-344

Doi:10.47582/jompac.1332258

View : 121 | Download : 42

Publication Date : 2023-08-30

Article Type : Research Paper

Abstract :Aims: We aimed to investigate the pre-treatment prognostic significance of lymphocyte/C-Reactive protein ratio insert ignore into journalissuearticles values(LCR);, one of the inflammatory factors, in patients with extensive-stage small cell lung cancer insert ignore into journalissuearticles values(SCLC);. Methods: Medical records of 514 patients who were diagnosed with extensive-stage SCLC between 2010 and 2020 were examined retrospectively. LCR was calculated using the blood test results prior to chemotherapy. Results: The mean survival time for extensive-stage SCLC is 6 months insert ignore into journalissuearticles values(5.3-6.7);. A statistically significant difference exists between limited and extensive stages in terms of median overall survival insert ignore into journalissuearticles values(OS); insert ignore into journalissuearticles values(p<0.001);. The baseline LCR value of the patients was determined as 0.5 insert ignore into journalissuearticles values(0-311);. LCR exerts a statistically significant effect on overall survival insert ignore into journalissuearticles values(0.025);. Every 1 unit increase in LCR reduces death by 1.004 times. Conclusion: Pre-treatment LCR value can be used as an independent prognostic parameter associated with mean survival in extensive SCLC.
Keywords : küçük hücreli akciğer kanseri, lenfosit CRP oranı, prognostik faktör, sağkalım

ORIGINAL ARTICLE URL